The invention relates to sulphonamide derivatives of formula (I), where RC is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or RC forms together with the phenyl ring to which it is attached a benzodioxolyl group, or RC is -NR1R2, RA is a group having the formula (A), (B) or (C) RB is hydrogen or alkyl. The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).
The invention relates to sulphonamide derivatives of formula (I),
where
R
C
is optionally substituted 4-6-membered heterocyclic ring containing one or more N atoms, or
R
C
forms together with the phenyl ring to which it is attached a benzodioxolyl group, or
R
C
is —NR
1
R
2
,
R
A
is a group having the formula
R
B
is hydrogen or alkyl.
The invention also relates to the use of derivatives of formula (I) as inhibitors for collagen receptor integrins and a process for preparing sulphonamides of formula (I).
该发明涉及式(I)的磺胺基衍生物,
其中
R
C
是可选取代的含有一个或多个N原子的4-6元杂环环,或
R
C
与其连接的苯环一起形成苯二氧杂基团,或
R
C
是-NR
1
R
2
,
R
A
是具有式的基团
R
B
是氢或烷基。
该发明还涉及将式(I)的衍生物用作胶原受体整合素的抑制剂以及制备式(I)的磺胺基的方法。
11-Beta HSD1 inhibitors
申请人:Xiang Shaoyun Jason
公开号:US20060025445A1
公开(公告)日:2006-02-02
This invention relates to inhibiting 11-beta HSD1.
这项发明涉及抑制11-beta HSD1。
Inhibitors of 15-lipoxygenase
申请人:Murugesan Natesan
公开号:US20060063823A1
公开(公告)日:2006-03-23
The present invention provides inhibitors of 15-LO according to Formula I, pharmaceutical compositions containing such inhibitors and methods for treating diseases related to the 15-LO cascade using such compounds and compositions.
[EN] QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLINES UTILISÉS COMME INHIBITEURS DES KINASES AXL
申请人:MAX PLANCK GESELLSCHAFT
公开号:WO2009127417A1
公开(公告)日:2009-10-22
The present invention relates to novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.